Factor VIII Antigen, Activity, and Mutations in Hemophilia A.

Article Details


Nair PS, Shetty S, Ghosh K

Factor VIII Antigen, Activity, and Mutations in Hemophilia A.

Clin Appl Thromb Hemost. 2016 May;22(4):381-5. doi: 10.1177/1076029614562951. Epub 2014 Dec 29.

PubMed ID
25550078 [ View in PubMed

Factor VIII (FVIII) activity, antigen, and its gene mutation in patients may give us some insight into structure-activity relationship and probable reason for its low level in a particular patient. A total of 53 cases with hemophilia A and 17 normal individuals were analyzed for FVIII: C and FVIII: Ag levels along with their blood groups to determine their cross-reacting material (CRM) status. In all, 37 cases (18 moderate and 19 mild) were found to have discordant CRM status. Missense mutations (Ala723ThrandLys439Ser) and protein truncating changes (Trp1854*andArg2326*) were observed in 2 each of these cases. Although 37 (70%) of the 53 had discordant antigen-activity ratio, majority of those mutations produced FVIII with low FVIII-specific activity. However, 4 (7.5%) of the 53 mutations produced higher specific activity of FVIII. It is possible that these mutations either produce a secretory defect or an increased metabolic turnover to account for the low levels of FVIII with these mutations.

DrugBank Data that Cites this Article

NameUniProt ID
Coagulation factor VIIIP00451Details